JAMA Oncology Author Interviews podcast

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

0:00
15:06
Recuar 15 segundos
Avançar 15 segundos

Mais episódios de "JAMA Oncology Author Interviews"